Current therapies for the prevention and treatment of osteoporosis are limited by efficacy and patient compliance. RANKL/osteoprotegerin/RANK signaling regulates bone resorption and is essential ...

One major contributor to osteoporosis is estrogen deficiency, which is prevalent in postmenopausal women. Estrogen plays a vital role in maintaining bone density by inhibiting bone resorption and ...

“Our findings suggest that injectable hydrogels with localized anti-catabolic drug delivery can complement systemic ...

Nat Clin Pract Endocrinol Metab. 2008;4(9):514-523. Whether patients with high bone-turnover rates will derive most benefit from treatments that reduce bone resorption and turnover (and vice ...

Osteoporosis is a disease in which bone resorbs faster than it is formed, gradually weakening its structure over time and ...

Osteoporosis, which affects approximately ... bone begins to weaken when bone resorption exceeds bone formation. Circulating osteoclast precursor cells exacerbate bone resorption and loss by ...

Bones are the living tissue on which the human skeleton is constructed and play a key role in enabling physical movements.

The discovery of a family with sequence similarity 102 member A (Fam102a) protein as a novel bone remodeling factor that ...

Treatment with romosozumab led to improvements in bone microarchitecture among postmenopausal women with osteoporosis.

Clinicians should screen women 65 and older for bone density and osteoporosis, according to the U.S. Preventive Services Task Force. The task force, an independent panel of disease prevention ...

Researchers have combined injections of a novel hydrogel with systemic osteoporosis drugs in rats, achieving rapid local increases in bone density. The results offer hope for future fracture ...